ReviewCellular & molecular biology letters2025
MFSD2A: a molecular nexus linking blood-brain barrier, lipid metabolism, and ischemia-reperfusion injury.
Review in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- MFSD2A in health and disease: lysolipid transport, barrier physiology, and translational boundaries.Molecular biomedicine · 2026Review
- Lipid Metabolism Reprogramming in the Aging Brain: Glial-Mediated Pathogenic Mechanisms and Translational Strategies in Neurodegeneration.International journal of molecular sciences · 2026Review
- Astrocytic ACSBG1 depletion improves lipid-cytokine signaling and attenuates α-Synuclein pathology in a Parkinson's disease mouse model.bioRxiv : the preprint server for biology · 2026Article
- Alterations in the Components of the GABA-Glutamate System During ZIKV Infection: A Neuroscience Approach.International journal of molecular sciences · 2026Article
- Integrated multi-matrix metabolomics reveals gut microbiota-driven systemic metabolic alterations and therapeutic remodeling by fecal microbiota transplantation in autism spectrum disorder.Journal of translational medicine · 2026Article
- Lipidomic signatures associated with cognitive impairment in type 1 diabetes mellitus: a pilot study integrating clinical serum and mouse hippocampus.Journal of translational medicine · 2026Article
- Low atherogenic index of plasma is associated with spontaneous hemorrhagic transformation in acute ischemic stroke patients: a retrospective cohort study and predictive modeling based on machine learning.Lipids in health and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Major facilitator superfamily domain-containing protein 2A (MFSD2A) is a central molecular player in maintaining the blood-brain barrier (BBB). It exerts dual protective effects in ischemia-reperfusion injury (IRI): MFSD2A regulates the lipid composition of brain endothelial cell membranes through its sodium-dependent transport of docosahexaenoic acid-conjugated lysophosphatidylcholine (LPC-DHA); this lipid remodeling thereby maintains the characteristic low permeability of the BBB by suppressing caveolae-mediated transcytosis. This review systematically analyzes the tissue distribution patterns of MFSD2A, the protein structural features, and its biological functions both in physiological and pathological conditions. We further reveal its cell type-specific regulatory networks. Notably, acute-phase of IRI induces downregulation of MFSD2A and subsequent BBB leakage. MFSD2A not only serves as a molecular switch to enhance brain-targeted drug delivery (e.g., temporarily inhibiting its activity to improve nanoparticle transport across the BBB) but may also become a therapeutic target for maintaining BBB integrity (e.g., agonist development). This review provides a novel framework for understanding MFSD2A's multidimensional mechanisms in neurological diseases and its potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.